Search

Search Constraints

You searched for: Author/Creator D'Angelo, Sandra

Search Results

1. 297 Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers. (10th December 2020)

2. 297 Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers. (9th November 2020)

3. 368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors. (10th December 2020)

4. 368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors. (9th November 2020)

5. Clinical activity of ipilimumab for metastatic uveal melanoma. Issue 20 (2nd August 2013)

6. Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana‐Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan‐Kettering Cancer Center, and University Hospital of Lausanne experience. Issue 20 (2nd August 2013)

7. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. Issue 4 (1st April 2022)

8. Optimizing engineered TCR T cell therapy for synovial sarcoma. (4th November 2015)

9. Optimizing engineered TCR T cell therapy for synovial sarcoma. Issue 2 (December 2015)

10. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Issue 11 (November 2017)